Shots: BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy, safety and immunogenicity. Additionally, […]readmore
Tags : Partner
Shots: The designation is based on preliminary data from P-I/II study assessing BNT162b1 including animal immunogenicity studies results that were released on Jul 01, 2020. Additionally, the early results of […]readmore
Shots: The P-III trial involves assessing REGN-COV2 with an expected enrollment of 2000 patients at 100 sites which will be evaluated to prevent infection among uninfected people who have had […]readmore
The partner received Registration Certificate for its Acellbia (biosimilar, rituximab) and Herticad (biosimilars, trastuzumab) in Bosnia and Herzegovina, countries on the Balkan Peninsula in Southeastern EU. The Agency for Medicinal […]readmore
Shots: Mabpharm files Infliximab Biosimilar’s NDA to the NMPA based on the trial evaluating Infliximab Biosimilar vs Infliximab and has used CHO expression system which resulted in safety results and […]readmore
Shots: TeneoOne to receive $90M upfront and will take care of P-I trial for TNB-383B with its expected onset in H1’19. AbbVie to get exclusive WW rights to develop and […]readmore